Home
·
Contributors
·
Maria Dranishnikova
Maria Dranishnikova

Maria Dranishnikova

Oninvest reporter

Writes about:

Articles: 904

Freedom Broker recommended buying Intrepid shares / Photo: Facebook / IntrepidPotash
Small Caps·

Freedom was the first on Wall Street to believe in Intrepid, a small-cap potash producer. Why?

A Cathie Wood ETF has invested in Scribe, a clinical-stage developer of gene therapies for heart diseases / Photo: LinkedIn / Catherinedwood
Small Caps·

Cathie Wood's ARK Genomic Revolution ETF buys newly public biotech Scribe

Shutterstock has suspended its quarterly dividend and announced its chief accounting officer will resign / Photo: Facebook/Shutterstock
Small Caps·

Shutterstock hits all-time low on suspended dividend, accounting chief departure

A Nasdaq-listed company worth less than $5 million for 30 straight days would face immediate suspension and delisting with limited opportunities to appeal under the approved plan / Photo: JHVEPhoto / Shutterstock.com
Small Caps·

Nasdaq gets SEC OK for tighter rules on micro caps; almost 200 names face delisting

Sidus Spaces founder and CEO described a transition from primarily technology development to focus on commercialization, recurring revenue, and operating leverage / Photo: Facebook / Sidus.Space
Small Caps·

Sidus Space unveils shift from tech build to commercialization; stock jumps 17%

BTIG warns that the company faces mounting risks from AI, weakening traffic trends, and limited prospects for further strategic value creation / Photo: Facebook / TripAdvisor
Small Caps·

Citing AI risks, BTIG downgrades Tripadvisor to 'hold'

BTIG initiated coverage on Neuronetics with a buy rating and a target price of $5 / Photo: Facebook / NeuroStarAdvancedTMS
Small Caps·

Stock of depression drugmaker Neuronetics adds 25% after BTIG initiation at 'buy'

The company unveiled its autonomous aircraft with Anduril for defense use called Thunder / Photo: Facebook / Archer Aviation
Small Caps·

Air taxi company Archer unveils attack rotorcraft developed with Anduril; shares soar

A Motley Fool contributor advises being patient on Oklo and pushing the valuation out by a few years to set up a better risk-to-reward ratio / Photo: Facebook / Oklo
Small Caps·

Motley Fool calls Wall Street valuations on nuclear startup Oklo 'bit too optimistic'